Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

ung and ovarian cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

The primary objective of the trial was to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN when administered in combination with gemcitabine. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

Gemzar(R) is indicated for NSCLC, breast, pancreatic and ovarian cancer. For more information about Gemzar(R), please visit www.gemzar.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. and U.S. combination REOLYSIN/gemcitabine clinical trials and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue researc
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... New York, NY (PRWEB) May 22, 2013 ... My Cleaning Products said that there is a way to ... victims, it included on its latest post the details of ... spending too much money. , Mold could be prevented, My ... preventive measures, the company stated that a mold remediation must ...
(Date:5/22/2013)... A recent study from researchers in ... find that those who took probiotics were able to run ... study showed that in extreme heat conditions, probiotics were able ... acne treatment explains what this new discovery means ... their skin condition. , While researchers tote the benefits ...
(Date:5/21/2013)... Fla. , May 21, 2013  On ... FCN ), the global business advisory firm ... enterprise value (the "Company"), announced that it has ... that were formerly included within the Corporate Finance/Restructuring ... Consulting segment to form a single integrated practice ...
(Date:5/21/2013)... The results of a new study led by ... computational evidence that nucleation of ice in small ... understanding water,s behavior at the nanoscale. The formation ... basic scientific research question whose answer also has ... , The crystallization of ice from supercooled ...
Breaking Biology Technology:How to Kill Mold While Saving Thousands of Dollars on Mold Remediation Projects Explained by My Cleaning Products 2Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2
... PITTSBURGH, March 30 Mylan Inc. (Nasdaq: ... India-based subsidiary in which it holds a 71.2% controlling ... U.S. Food and Drug Administration (FDA) under the President,s ... New Drug Application (ANDA) for Emtricitabine and Tenofovir Disoproxil ...
... Inverness Medical Innovations, Inc. (NYSE: IMA ), a ... health at home through the merger of rapid diagnostics and ... on its Series B Convertible Perpetual Preferred Stock (NYSE: IMA-PB). ... stock in an amount per share equal to the quotient ...
... Inc. (Nasdaq: GSIG ), a supplier of precision ... errors related to timing of the recognition of revenue from ... fiscal year 2006. The Audit Committee of the Board of ... potential adjustments resulting from the identified errors is material to ...
Cached Biology Technology:Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R) 2GSI Group Inc. to Restate Financial Results for 2006 2
(Date:5/20/2013)... the antibiotic colistin are also commonly resistant to ... to a study in mBio , the ... Microbiology. Cross-resistance to colistin and host antimicrobials LL-37 ... bacterial attack, could mean that patients with life-threatening ... crippled immune response. Colistin is a last-line drug ...
(Date:5/20/2013)... effect of physical education (PE) on child weight, but ... the amount of time that elementary schoolchildren spent in ... study represents some of the first evidence of a ... forthcoming in the Journal of Health Economics . ... be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The research ...
(Date:5/20/2013)... COLUMBUS, Ohio New research suggests that a compound ... "superpower" to escape death. , By altering a ... re-educates cancer cells into normal cells that die as ... by inhibiting a process that would cause them to ... strict programming. This study in cells, led by Ohio ...
Breaking Biology News(10 mins):Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3Gym class reduces probability of obesity, study finds for first time 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3
... of Medicine (BCM) in Houston have reason to believe ... or control HIV infection, according to a study published ... , The study in mice boosted the immune response ... the immune system's full potential in conjunction with conventional ...
... of evolutionary detective work. Biology researchers at Lewis & ... evidence for an ancient transfer of a toxin between ... But the mystery remains as how the toxin passed ... month in the journal Bioinformatics, 22(3): 264-268, in an ...
... Weizmann Institute of Science recently discovered a new source ... were published in the Proceedings of the National Academy ... source of information on the evolution, population dynamics, migrations, ... it is not well preserved or becomes contaminated by ...
Cached Biology News:HIV vaccine takes different tack to boosting immune response 2Evolution mystery: Spider venom and bacteria share same toxin 2Ancient fossil DNA found preserved in crystal 2